Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
MAXCYTE, INC. (MXCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/12/2023 |
4
| Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Sold 445 shares
@ $5.01, valued at
$2.2k
Sold 12,798 shares
@ $5.04, valued at
$64.5k
Sold 16,757 shares
@ $5.02, valued at
$84.1k
Exercised 445 options to buy
@ $0.04, valued at
$17.8
Exercised 12,798 options to buy
@ $0.04, valued at
$511.9
Exercised 16,757 options to buy
@ $0.04, valued at
$670.3 |
|
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/28/2023 |
4
| Johnston John Joseph (Director) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Sold 7,529 shares
@ $4.49, valued at
$33.8k
Sold 7,471 shares
@ $4.39, valued at
$32.8k
Exercised 6,817 options to buy
@ $0.983, valued at
$6.7k
Exercised 712 options to buy
@ $1.641, valued at
$1.2k
Exercised 7,471 options to buy
@ $1.641, valued at
$12.3k
|
|
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
4
| Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Sold 16,149 shares
@ $5.02, valued at
$81.1k
Exercised 16,149 options to buy
@ $0.04, valued at
$646 |
|
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/04/2023 |
4
| Ross Thomas M. (EVP, Global Sales & Marketing) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Sold 2,607 shares
@ $5, valued at
$13k
Sold 100 shares
@ $5.01, valued at
$501
Sold 7,266 shares
@ $5.03, valued at
$36.5k
Exercised 2,607 options to buy
@ $2.142, valued at
$5.6k
Exercised 100 options to buy
@ $2.142, valued at
$214.2
Exercised 7,266 options to buy
@ $2.142, valued at
$15.6k
|
|
| 04/04/2023 |
4
| Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Sold 2,607 shares
@ $5, valued at
$13k
Sold 100 shares
@ $5.01, valued at
$501
Sold 7,470 shares
@ $5.03, valued at
$37.6k
Exercised 2,607 options to buy
@ $0.04, valued at
$104.3
Exercised 100 options to buy
@ $0.04, valued at
$4
Exercised 7,470 options to buy
@ $0.04, valued at
$298.8 |
|
| 03/30/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
4
| Holtz Ron (CFO) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Granted 120,000 options to buy
@ $4.19, valued at
$502.8k
|
|
| 03/21/2023 |
4
| Hemrajani Rekha (Director) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Granted 40,000 options to buy
@ $4.19, valued at
$167.6k
|
|
| 03/21/2023 |
4
| Al-Wakeel Yasir B. (Director) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Granted 40,000 options to buy
@ $4.19, valued at
$167.6k
|
|
| 03/21/2023 |
4
| Masoud Maher (EVP and General Counsel) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Granted 120,000 options to buy
@ $4.19, valued at
$502.8k
|
|
| 03/21/2023 |
4
| Ross Thomas M. (EVP, Global Sales & Marketing) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Granted 120,000 options to buy
@ $4.19, valued at
$502.8k
|
|
| 03/21/2023 |
4
| Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Granted 400,000 options to buy
@ $4.19, valued at
$1.7M
|
|
| 03/21/2023 |
4
| Sumen Cenk (Chief Scientific Officer) has filed a Form 4 on MAXCYTE, INC.|
Txns:
| Granted 500,000 options to buy
@ $5.7, valued at
$2.9M
Granted 120,000 options to buy
@ $4.19, valued at
$502.8k
|
|
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.6% stake in MAXCYTE, INC. |
| 01/10/2023 |
SC 13G/A
| Casdin Capital, LLC reports a 9% stake in MaxCyte, Inc. |
|
|
|